Navigation Links
Combo Drug Therapy May Work Best to Strengthen Bones: Study
Date:5/14/2013

By Dennis Thompson
HealthDay Reporter

TUESDAY, May 14 (HealthDay News) -- A new combination drug therapy for osteoporosis appears to increase bone density more effectively than any treatment now on the market, according to the results of a small clinical trial.

Researchers found that postmenopausal women experienced significant amounts of bone growth by taking a bone-building drug called teriparatide with denosumab, a targeted therapy drug used to stop bone loss.

"A combination of these two medications increased bone density more than either does on its own, and it is more effective than any currently approved therapy," said study author Dr. Benjamin Leder, who is with the endocrine unit at Massachusetts General Hospital in Boston.

The 12-month study, published online May 15 in The Lancet, was funded in part by the drugs' makers, Eli Lilly and Amgen. It involved 94 postmenopausal women being treated for osteoporosis, a bone-thinning disorder common in old age that makes bones more likely to break.

Researchers divided the group into thirds, with one third receiving a combination therapy of teriparatide (Forteo) and denosumab (Prolia), and the rest taking one medication or the other.

Those treated with both drugs enjoyed significantly better results than those receiving just one. For example, bone density measured at the lumbar spine increased 6.2 percent with teriparatide alone and 5.5 percent with denosumab alone, but combination treatment resulted in a 9.1 percent increase. Bone density at the hip increased 4.9 percent with the combination treatment versus 2.5 percent with denosumab and 0.7 percent with teriparatide.

Bones are in constant flux, with one set of cells forming new bone while other cells break down bone through a process called resorption. After women go through menopause, resorption begins to outpace the formation of new bone, leading to bone thinning and an increased ri
'/>"/>

Copyright©2012 ScoutNews,LLC.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Experimental Chemo Combo for Colon Cancer Disappoints
2. Value of Metformin, Insulin Combo for Type 2 Diabetes Questioned
3. Two-Drug Combo Helps Teens With Migraines
4. Two-Drug Combo May Be Safe for Melanoma Treatment
5. Breast cancer clinical trial tests combo of heat shock protein inhibitor and hormonal therapy
6. Combo Therapy May Help Ease Ringing in the Ears
7. FDA Approves Combo Shot for Meningitis, Hib in Kids
8. Booze, Energy Drinks, Casual Sex Combo Common in College: Study
9. Drug combo better for common type of metastatic breast cancer, UCI-led study finds
10. Double drug combo could shut down abnormal blood vessel growth that feeds disease
11. Cooking-Oil Combo May Improve Blood Pressure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... from the University of Adelaide have developed a model ... a good outcome from treatment - from their very ... a range of factors, including clinical symptoms, cognitive abilities, ... the patient,s blood. , Speaking in the lead up ... Head of Psychiatry , Professor Bernhard Baune ...
(Date:10/1/2014)... research co-funded by the Engineering and Physical Sciences ... of the UK,s vital industrial control systems which ... electricity grid, and the rail network. , ... from hackers or malware infiltrating the systems behind ... Institute in Trustworthy Industrial Control Systems (RITICS), based ...
(Date:10/1/2014)... 01, 2014 Marriagelifeinsurance.com has released ... insurance for retired couples. , Senior citizens can ... security for their loved ones. A joint policy is ... persons pass away. , Life insurance can be ... insurance can even be purchased online, as the application ...
(Date:10/1/2014)... October 01, 2014 Phoseon Technology, the ... continues to expand the business worldwide. This rapid growth ... additional capacity for manufacturing efforts. The company has experienced ... five years and expects this growth to continue in ... technology gains worldwide adoption. , “We are very ...
(Date:10/1/2014)... Beverly Hills, California (PRWEB) October 01, 2014 ... relationship expert, Dr. Kathleen Mojas is celebrating 20 years ... she has assisted hundreds of people to achieve greater ... released an important list of warning signs and suggestions ... relationship. , Dr. Mojas explains: “Believe it or ...
Breaking Medicine News(10 mins):Health News:Predicting the future course of psychotic illness 2Health News:£2.5 million to recognize and reduce cyber-attack threats to critical infrastructure 2Health News:Elderly Life Insurance - Find Life Insurance for Retired Couples! 2Health News:Phoseon Technology Continues to Drive Growth Worldwide 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 3
... eye mainly during the surgical treatment of retinal hemorrhages or ... the detached retina to the wall of the eye. There ... during airplane travel, at high altitudes, or under nitrous oxide ... risk remains present for weeks after the surgical procedure. , ...
... ATLANTA, Feb. 25 CIBER, Inc. ... and implemented a service-oriented,architecture (SOA)-based software application ... for Disease Control and Prevention (CDC). CDCAS,reliably, ... and public,health organizations of disease outbreaks, bioterrorism ...
... small-diameter implants expanded more than 30% in 2007, ... according to Millennium Research Group, ... shows that small-diameter (less than or equal to 3.0 mm),dental ... implants are growing at a faster rate than those of ...
... Park have discovered that Normal Human Bronchial Epithelial (NHBE) ... the high end of plasma zinc attainable by oral ... arrest and DNA damage-induced gene (Gadd45) mRNA and protein ... research, published in the March 08 issue of the ...
... February 24, 2008: With a deep understanding of healthcare ... a global medical publisher, Elsevier is broadening its efforts ... (CDS) tools that help providers make optimal decisions at ... acquired CPM Resource Center, a provider of interactive nursing ...
... who examined blood test records in a survey of over ... found thousands of cases of probable undiagnosed diabetes. This could ... in UK. , The research is published in the ... was led by Dr Tim Holt of the University of ...
Cached Medicine News:Health News:CDC Uses CIBER-Built Solution to Alert Public Health Officials and Public Health Departments 2Health News:CDC Uses CIBER-Built Solution to Alert Public Health Officials and Public Health Departments 3Health News:CDC Uses CIBER-Built Solution to Alert Public Health Officials and Public Health Departments 4Health News:Small-Diameter Dental Implants Increasingly Popular In the US 2Health News:High zinc status in lung cells slows growth and induces DNA damage-induced gene expression 2Health News:High zinc status in lung cells slows growth and induces DNA damage-induced gene expression 3Health News:Elsevier enhances clinical decision making with suite of Clinical Decision Support solutions 2Health News:Elsevier enhances clinical decision making with suite of Clinical Decision Support solutions 3Health News:Elsevier enhances clinical decision making with suite of Clinical Decision Support solutions 4Health News:GP's databases could identify tens of thousands with undiagnosed diabetes in UK 2
(Date:10/2/2014)... 1, 2014   Intarcia Therapeutics, Inc. today ... phase 3 clinical trials for ITCA 650 (exenatide, delivered ... osmotic mini-pump). The first trial, FREEDOM-1, was a placebo-controlled, ... and safety of ITCA 650 in patients with type ... to be significantly superior to placebo for both 40 ...
(Date:10/1/2014)... 1, 2014  Dyadic International, Inc. ("Dyadic") (OTCQX: ... proprietary technology used to develop and produce enzymes ... biopharmaceuticals, and industrial enzymes industries, today announced the ... Bioenergy for commercial scale production of Abengoa,s proprietary ... developed under Abengoa,s license agreement with Dyadic. ...
(Date:10/1/2014)... NeuroCall, Inc., ("NeuroCall") announced today that it ... Teleneurology services. Dr. Ricardo Garcia-Rivera , Founder and ... proud that our quality of service has been recognized ... lifesaving support and continuity of care to patients of ... the United States ." NeuroCall ...
Breaking Medicine Technology:Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 2Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 3Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 4Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 5Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 2Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 3NeuroCall Awarded Joint Commission Accreditation 2
... Ltd. (NYSE Amex: CPD ) announced that ... (Sun) have been extended until January 28, 2012 but ... which was originally set to expire in January 2010, ... and is being extended for an additional 1 year ...
... Pharmaceutical Company (NYSE: KVa/KVb) today announced the filing of its ... with the Securities and Exchange Commission.  As a result, the ... 2010 Form 10-K to enable its securities to continue trading ... is currently working on preparing and filing its quarterly reports ...
Cached Medicine Technology:Caraco Pharmaceutical Laboratories, Ltd. Announces Extension and Future Termination of Distribution Agreements with Sun Pharma 2Caraco Pharmaceutical Laboratories, Ltd. Announces Extension and Future Termination of Distribution Agreements with Sun Pharma 3K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission 2K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission 3K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission 4K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission 5K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission 6K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission 7K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission 8
The Vitatron Excellence S+ lead series are endocardial leads providing excellent reliability and optimal pacing characteristics....
CapSure SP Novus endocardial, tined pacing leads provide the stable, low pacing thresholds and large sensing potentials already proven with CapSure SP steroid-eluting leads but within an even smaller...
Bipolar Atrial "J" Lead...
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
Medicine Products: